The most-read article this month was a look at the new European valve guidelines, with the list fleshed out by news from ESC 2025.

In postmenopausal women with type 2 diabetes, oral hormone replacement therapy (HRT) may increase the risk of CV events. Presenting data from a real-world study at the recent European Association for ...

The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms.

Vocal monitoring has the potential to identify HF patients with worsening congestion early and prevent acute decompensation.

It’s meant to support the valve guidelines and aid in disentangling the complexities of the tricuspid field, one of the authors says.

Implanting pacemakers in those who meet criteria for prophylactic use appears to be overtreating some patients.

The trial’s findings will dampen enthusiasm for the drug in stroke recovery, though research questions remain, one expert says.

The new SCAI initiative brings optimism for a population that has seen little innovation or changes to treatment paradigms in years.

In 2023, there were 437 million disability-adjusted life-years lost from cardiovascular disease, up from 320 million in 1990.

The TCTMD team discusses their favorite stories from this past month, while special guest Robert Roswell breaks down the DAPT-SHOCK-AMI trial from ESC 2025.